Preliminary Evaluation of the Effect of Investigational Ebola Virus Disease Treatments on Viral Genome Sequences

Journal of Infectious Diseases

Volumn 214, Issue , 2016, Pages S333-S341

  Whitmer, Shannon L M ^a   Albariño, César ^a   Shepard, Samuel S ^a   Dudas, Gytis ^c   Sheth, Mili ^b   Brown, Shelley C ^a   Cannon, Deborah ^a   Erickson, Bobbie R ^a   Gibbons, Aridth ^a   Schuh, Amy ^a   Sealy, Tara ^a   Ervin, Elizabeth ^a   Frace, Mike ^b   Uyeki, Timothy M ^a   Nichol, Stuart T ^a   Ströher, Ute ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Biotechnology Core Facility Branch   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Antiviral agents; Directed molecular evolution.; Ebola virus; High throughput nucleotide sequencing; Molecular epidemiology

Indexed keywords

BRINCIDOFOVIR; EPITOPE; RNA POLYMERASE; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA;

AMERICAN; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL EVALUATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS DISEASE; EBOLAVIRUS; FILOVIRUS INFECTION; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA EXTRACTION; RNA SEQUENCE; SINGLE DRUG DOSE; VIRUS GENOME; VIRUS ISOLATION; VIRUS MUTATION; WEST AFRICAN; CONVALESCENCE; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HEMORRHAGIC FEVER, EBOLA; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; MOLECULAR EPIDEMIOLOGY; MOLECULAR EVOLUTION; MUTATION; PLASMA; VIROLOGY;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CONVALESCENCE; DRUG RESISTANCE, VIRAL; EBOLAVIRUS; EVOLUTION, MOLECULAR; GENOME, VIRAL; HEMORRHAGIC FEVER, EBOLA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR EPIDEMIOLOGY; MUTATION; PLASMA; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, DNA;

EID: 84990963254     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw177     Document Type: Article

References (43)

1. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014; 371:1418-25.
2. Kuhn JH, Andersen KG, Baize S, et al. Nomenclature-and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014. Viruses 2014; 6:4760-99.
3. WHO. Ebola response roadmap situation report 17 February 2016. http://www.who.int/csr/disease/ebola/situation-reports/en. Accessed 20 February 2016.
4. Brouqui P, Ippolito G. Ebola and travel-management of imported cases. Travel Med Infect Dis 2014; 12:561-2.
5. Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014; 371:2402-9.
6. Kreuels B, Wichmann D, Emmerich P, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 2014; 371:2394-401.
7. Uyeki TM, Mehta AK, Davey RT Jr, et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med 2016; 374:636-46.
8. Gire SK, Goba A, Andersen KG, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 2014; 345:1369-72.
9. Hoenen T, Safronetz D, Groseth A, et al. Mutation rate and genotype variation of Ebola virus from Mali case sequences. Science 2015; 348:117-9.
10. Tong YG, Shi WF, Liu D, et al. Genetic diversity and evolutionary dynamics of Ebola virus in Sierra Leone. Nature 2015; 524:93-6.
11. Carroll MW, Matthews DA, Hiscox JA, et al. Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa. Nature 2015; 524:97-101.
12. Kugelman JR, Wiley MR, Mate S, et al. Monitoring of Ebola virus Makona evolution through establishment of advanced genomic capability in Liberia. Emerg Infect Dis 2015; 21:1135-43.
13. Park DJ, Dudas G,Wohl S, et al. Ebola virus epidemiology, transmission, and evolution during seven months in Sierra Leone. Cell 2015; 161:1516-26.
14. Chevalier MS, Chung W, Smith J, et al. Ebola virus disease cluster in the United States-Dallas County, Texas, 2014. MMWR Morb Mortal Wkly Rep 2014; 63:1087-8.
15. Liddell AM, Davey RT Jr, Mehta AK, et al. Characteristics and clinical management of a cluster of 3 patients with Ebola virus disease, including the first domestically acquired cases in the United States. Ann Intern Med 2015; 163:81-90.
16. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514:47-53.
17. Qiu X, Audet J, Wong G, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012; 4:138ra81.
18. Qiu X, Alimonti JB, Melito PL, Fernando L, Stroher U, Jones SM. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol 2011; 141:218-27.
19. Jones S, Qiu X, Feldmann H, Stroeher U. Monoclonal antibodies for Ebola and Marburg viruses, 2013. US Patent number 9,249,214.
20. Wilson JA, Hevey M, Bakken R, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000; 287:1664-6.
21. Kraft CS, Hewlett AL, Koepsell S, et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis 2015; 61:496-502.
22. Florescu DF, Kalil AC, Hewlett AL, et al. Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin Infect Dis 2015; 61:969-73.
23. Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proofof-concept study. Lancet 2010; 375:1896-905.
24. Beadle JR, Hartline C, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002; 46:2381-6.
25. Kern ER, Hartline C, Harden E, et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002; 46:991-5.
26. Chimerix I. Chimerix's brincidofovir has in vitro activity against Ebola [news release] 2014. http://ir.chimerix.com/releasedetail.cfm?ReleaseID=868807. Accessed 20 February 2016.
27. McMullan LK, Flint M, Dyall J, et al. The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus. Antiviral Res 2016; 125:71-8.
28. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 2009; 82:A84-98.
29. James SH, Price NB, Hartline CB, Lanier ER, Prichard MN. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. Antimicrob Agents Chemother 2013; 57:3321-5.
30. Chou S, Marousek G, Guentzel S, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997; 176:786-9.
31. Palacios G, Quan PL, Jabado OJ, et al. Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis 2007; 13:73-81.
32. Carroll SA, Towner JS, Sealy TK, et al. Molecular evolution of viruses of the family Filoviridae based on 97 whole-genome sequences. J Virol 2013; 87:2608-16.
33. Thi EP, Mire CE, Lee AC, et al. Lipid nanoparticle siRNA treatment of Ebolavirus-Makona-infected nonhuman primates. Nature 2015; 521:362-5.
34. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 1996; 93:3602-7.
35. Loman NJ, Misra RV, Dallman TJ, et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012; 30:434-9.
36. Audet J, Wong G, Wang H, et al. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci Rep 2014; 4:6881.
37. Dallas A, Ilves H, Ma H, et al. Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy. J Virol 2014; 88:4647-56.
38. Parker JS, Roe SM, Barford D. Molecular mechanism of target RNA transcript recognition by Argonaute-guide complexes. Cold Spring Harb Symp Quant Biol 2006; 71:45-50.
39. Kugelman JR, Sanchez-Lockhart M, Andersen KG, et al. Evaluation of the potential impact of ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics. mBio 2015; 6:e02227-14.
40. Tekmira provides update on TKM-Ebola-Guinea [news release]. http://investor. tekmirapharm.com/releasedetail.cfm?ReleaseID=918694. Accessed 20 February 2016.
41. WHO. Ebola treatments and interventions. http://www.who.int/medicines/ebolatreatment/ebola-drug-clinicaltrials/en/. Accessed 20 February 2016.
42. PainterW, Robertson A, Trost LC, Godkin S, Lampert B, Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012; 56:2726-34.
43. Hartlieb B, Muziol T, Weissenhorn W, Becker S. Crystal structure of the C-terminal domain of Ebola virus VP30 reveals a role in transcription and nucleocapsid association. Proc Natl Acad Sci U S A 2007; 104:624-9.